Suven Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 07, 2025, titled "Press release regarding change in name of the Company".
COHANCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Suven Pharmaceuticals Limited has officially been renamed to Cohance Lifesciences Limited, effective May 7, 2025, with approval from the Ministry of Corporate Affairs. The name change was carried out as part of a previously announced Scheme of Amalgamation and reflects the company's evolution into a global, technology-driven CDMO (Contract Development and Manufacturing Organization) platform. The new name 'Cohance' represents the company's commitment to collaborating with innovators to enhance molecules and products for patients worldwide. The company reported consolidated revenue of US$318 million (LTM, Dec24) and has strengthened its capabilities through recent acquisitions of Sapala (oligonucleotides) and NJ Bio (ADC technology). Applications will be made to BSE and NSE to update the company name in their records.
Existing shareholders continue to own the same company — only the brand name and identity have changed. The stock will continue trading under the existing scrip code (543064) and symbol (SUVENPHAR) until exchanges formally update the name, so there is no immediate action required from investors.